Manajemen Pemberian Antibiotik dengan Hasil Uji Kepekaan Resisten

Deny Perdana Putra, Tutik Kusmiati

Abstract views = 760 times | downloads = 4952 times


The use of antibiotics in developed countries 13-37% and 30-80% in developing countries. Inappropriate use of antibiotics around 40-62%. There is a relationship between the use of antibiotics in bacterial resistance. Reported a man, 45 years old with a diagnosis of pneumonia + sepsis + DM Type 2 + hypoalbuminemia + anemia + suspek nephrotic syndrome. Empirical therapy is given Meropenem and Levofloxacin 1 750 3 1 grams milligrams. Evaluation after empirical therapy showed no improvement clinically and radiologically. The result of the patient ‘s sputum cultures of Pseudomonas aeruginosa which are resistant to antibiotics tested, therefore the definitive therapy can not be given based on antibiotic susceptibility. The cause of this multifactorial resistance in patients with Pseudomonas resistance to antibiotics through four mechanisms. Therefore, definitive therapy based on local patterns of bacteria and sensitivity test on pneumonia issued by the Department of Microbiology Clinic. Based on the data, antibiotic Piperacillin-tazobactam 4 4, 5 grams are then administered. The results of the evaluation of clinical, radiological and laboratory showed significant improvements in patients.


Pneumonia, Pseudomonas aeruginosa, Antibiotic resistance, Sensitivity pattern of bacteria and germs local test

Full Text:



WHO, Drug and therapeutic committees. A practical guide. Departement of essential drugs and medicines policy. Geneva, Switzerland. 2003.

Lestari wulan, Zubril nasrul, A. almahdy, Darwin deswinar. Studi penggunaan antibiotik berdasarkan system ATC/DDD dan kriteria gyysens. RSUP. Dr. M. Djamil/Universitas Andalas, Padang. 2011.

Peraturan Menteri Kesehatan Republik Indonesia Nomor 2406/ Menkes/PER/XII/2011. Tentang pedoman umum penggunaan antibiotik. Menteri Kesehatan Republik Indonesia. 2011.

Kementerian Kesehatan Republik Indonesia. Pedoman pelayanan kefarmasian untuk terapi antibiotik. 2011.

H. yulia. Pola resistensi antibiotik. Fakultas Kedokteran Universitas Indonesia. 2009.

Pneumonia Komuniti, Pedoman Diagnosis dan Penatalaksanaan di Indonesia. Perhimpunan Dokter Paru Indonesia, 2003.

Shigeki F, Hsin Y S, Victor L, Jeremy AW. Pneumonia due to Pseudomonas aeruginosa Part I: Epidemiology, Clinical Diagnosis and Source. Chest. 2011; 139(4): 909-919.

Pneumonia nosokomial, Pedoman Diagnosis dan Penatalaksanaan di Indonesia, Perhimpunan Dokter Paru Indonesia 2003.

Utami Eka Rahayu. Antibiotika, Resistensi, dan Rasionalitas Terapi. Sainstis volume 1, Nomor 1, April-September 2012.

Bari S.B., Mahajan B.M., Surana S.J., Resistance to antibiotic: A challenge in chemotherapy. Indian journal of pharmaceutical education and research 2008.

Keputusan Menteri Kesehatan tentang standard pelayanan farmasi di Rumah Sakit No. 1197/Menkes/SK/X/2004.

Sadikot RT, Blackwell TS, Christman JW, Prince AS. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med. 2005; 171(11): 1209-1223.

Ma L, ConoverM, Lu H, Parsek MR, Bayles K, Wozniak DJ. Assembly and development of the Pseudomonas aeruginosa biofilm matrix. PloS Pathog. 2009; 5(3): e1000354.

Goossens H. Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group. Clin Microbial Infect. 2003; 9(9): 980-983.

Balcht, Aldona & Smith, Raymond (1994). Pseudomonas aeruginosa: Infections and Treatment. Informa Health Care. pp. 83-84.ISBN0- 8247-9210-6.

Flanagan JL, Brodie EL, Weng L et al. Loss of bacterial diversity during antibiotic treatment of intubated patients colonized with Pseudomonas aeruginosa. J Clin Microbiol. 2007; 45(6): 1954- 1962.

Mesaros N, Nordmanss P, Plesiat P, et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millenium. Clin Microbial Infect. 2007; 13(6): 560-578.

Walsh TR. Clinically significant carbapenemases: an update. Curr Opin Infect Dis. 2008; 21(4): 367-371.

Poole K. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005; 49(2): 479-487.

Dambrava PG, Torres A, Valles X et al. Adherence to guidelines empirical antibiotic recommendations and community-acquired pneumonia outcome. Eur Respir J. 2008;32(4): 892-901.

Ishida H, Ishida Y, Kurosaka Y, Otani T. In vitro and in vivo activities of Levofloxacin against biofilm-producing Pseudomonas aeruginosa. J Antimicrob Chemother. 1998; 42(7): 1641-1645.

Karlowsky JA, Kelly LJ. Thornsberry C et al; The surveillance network. Susceptibility to fluoroquinolone among commonly isolated gram negative bacili in 2000. TRUST and TSN data for United States. Tracking resistance in the United States today. Int J Antimicrob Agents. 2002;19(1): 21-31.

Hoyle BD,Wong CKW, Costerton JW. Disparate efficacy of tobramycinon Ca_2-, Mg_2-, and HEPES-treated Pseudomonas aeruginosa biofilms.Can J Microbiol 1992; 38: 1214-8.

Ceri H, Olson ME, Stremick C, et al. The Calgary biofilm device: newtechnology for rapid determination of antibiotic susceptibilities of bacterialbiofilms. J Clin Microbiol 1999; 37: 1771-6.

Kar A. Medical chemistry. New age international publishers. 2007.


Kuswandi. Identifikasi mutan-mutan Klebsiella pneumonia yang resisten terhadap antibiotika BRL 41897A dengan metode Southern Blot. Majalah Farmasi Indonesia. 2002; 13(4): 192-5.

Herdiman T.P, Suhendro, Djoko W.S. Penggunaan sefalosporin oral pada infeksi komunitas. Current treatment in internal medicine 2000. Jakarta. Pusat Informasi dan Penerbitan Departemen Ilmu Penyakit Dalam FKUI. 2000: 119-24.


  • There are currently no refbacks.

View My Stats



Creative Commons License

JR (p-ISSN: 2407-0831e-ISSN: 2621-8372) is licensed under Creative Commons Attribution-ShareAlike 4.0 International License.